Partner David Rosen told Pink Sheet in an article, “FDA Gives Congress Reprieve on Deadline for Passing User Fee Bill,” that most Senators are still pushing to get the FDA Reauthorization Act done prior to October 1, 2017.
FDA Commissioner Gottlieb recently sent a memo to all FDA employees that it does not plan to send reduction in force notices on August 1, 2017 to employees that could lose their jobs if FDARA is not enacted by October 1, 2017. “Gottlieb would not be telling employees about his plans unless the agency was “comfortable that they have assurances that the bill is going to pass,” Rosen said.
(Subscription required to read)
People
Related News
06 February 2025
In the News
Vanessa Miller Assesses Panama Canal Discourse
Foley & Lardner LLP partner Vanessa Miller commented in SupplyChainBrain article, "The Fight for Control of the Panama Canal," lending important context to the recent headlines over the important waterway.
06 February 2025
In the News
Gregory Husisian Weighs in on Suspension of De Minimis Trade Exemption
Foley & Lardner LLP partner Gregory Husisian offered context on President Trump's recent trade actions on China in The Wall Street Journal article, "Why Trump Is Closing a Trade Exemption for China."
04 February 2025
In the News
Andrew Wronski on Tariff Fluidity – 'Keep on top of the issues'
Foley & Lardner LLP partner Andrew Wronski assessed the evolving shift in U.S. trade policy in the Milwaukee Business Journal article, "Trump tariffs won't disappear — so how should Wisconsin businesses prepare?"